Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Praziquantel and antiretroviral drug-drug interaction study
PACTR202102566734864Phase 1Completed
- Sponsor
- AiBST
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of praziquantel, efavirenz and ritonavir in schistosomiasis and human immunodeficiency virus infection (HIV), sponsored by AiBST. Primary endpoints: Area under the concentration-time curve and Maximum plasma concentration. Started May 2019; status: completed.
02
Drugs
praziquantelefavirenzritonavir
03
Conditions
schistosomiasishuman immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202102566734864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202102566734864.